In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6342-6352

  Call, Melissa J ^a   Xing, Xuechao ^b   Cuny, Gregory D ^b,c   Seth, Nilufer P ^d   Altmann, Daniel M ^e   Fugger, Lars ^f   Krogsgaard, Michelle ^g   Stein, Ross L ^b,c   Wucherpfennig, Kai W ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b The Harvard Center for Neurodegeneration & Repair   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PFIZER INC   (United States)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; APC PROTEIN; HLA DM ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYST; CELL SURFACE; CHEMICAL STRUCTURE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR SIZE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGEN PRESENTATION; HLA-D ANTIGENS; HLA-DR ANTIGENS; MICE; MICE, TRANSGENIC; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349119901     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803464     Document Type: Article

References (48)

1. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25: 821-852.
2. Zhu, J., and W. E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood 112: 1557-1569.
3. Davies, J. L., Y. Kawaguchi, S. T. Bennett, J. B. Copeman, H. J. Cordell, L. E. Pritchard, P. W. Reed, S. C. Gough, S. C. Jenkins, S. M. Palmer, et al. 1994. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371: 130-136.
4. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. de Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, et al. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862. (Pubitemid 47347319)
5. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
6. Natarajan, S. K., M. Assadi, and S. Sadegh-Nasseri. 1999. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J. Immunol. 162: 4030-4036.
7. Germain, R. N., and A. G. Rinker, Jr. 1993. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363: 725-728.
8. Rabinowitz, J. D., M. Vrljic, P. M. Kasson, M. N. Liang, R. Busch, J. J. Boniface, M. M. Davis, and H. M. McConnell. 1998. Formation of a highly peptide-receptive state of class II MHC. Immunity 9: 699-709.
9. Joshi, R. V., J. A. Zarutskie, and L. J. Stern. 2000. A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry 39: 3751-3762. (Pubitemid 30183857)
10. Roche, P. A., and P. Cresswell. 1991. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc. Natl. Acad. Sci. USA 88: 3150-3154.
11. Riberdy, J. M., J. R. Newcomb, M. J. Surman, J. A. Barbosa, and P. Cresswell. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360: 474-477.
12. Lanzavecchia, A., P. A. Reid, and C. Watts. 1992. Irreversible association of peptides with class II MHC molecules in living cells. Nature 357: 249-252.
13. Morris, P., J. Shaman, M. Attaya, M. Amaya, S. Goodman, C. Bergman, J. J. Monaco, and E. Mellins. 1994. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368: 551-554. (Pubitemid 24118772)
14. Sloan, V. S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, and D. M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375: 802-806.
15. Denzin, L. K., and P. Cresswell. 1995. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 82: 155-165.
16. Grotenbreg, G. M., M. J. Nicholson, K. D. Fowler, K. Wilbuer, L. Octavio, M. Yang, A. K. Chakraborty, H. L. Ploegh, and K. W. Wucherpfennig. 2007. Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association. J. Biol. Chem. 282: 21425-21436.
17. Denzin, L. K., C. Hammond, and P. Cresswell. 1996. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184: 2153-2165.
18. Kropshofer, H., S. O. Arndt, G. Moldenhauer, G. J. Hammerling, and A. B. Vogt. 1997. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6: 293-302. (Pubitemid 27148596)
19. vogt, A. B., G. Moldenhauer, G. J. Hammerling, and H. Kropshofer. 1997. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion. Immunol. Lett. 57: 209-211.
20. Sanderson, F., M. J. Kleijmeer, A. Kelly, D. Verwoerd, A. Tulp, J. J. Neefjes, H. J. Geuze, and J. Trowsdale. 1994. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 266: 1566-1569.
21. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364: 33-39.
22. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215-221. (Pubitemid 24108837)
23. Doebele, R. C., R. Busch, H. M. Scott, A. Pashine, and E. D. Mellins. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13: 517-527.
24. Pashine, A., R. Busch, M. P. Belmares, J. N. Munning, R. C. Doebele, M. Buckingham, G. P. Nolan, and E. D. Mellins. 2003. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 19: 183-192. (Pubitemid 37011333)
25. Stratikos, E., L. Mosyak, D. M. Zaller, and D. C. Wiley. 2002. Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis. J. Exp. Med. 196: 173-183. (Pubitemid 34787507)
26. Ullrich, H. J., K. Doring, U. Gruneberg, F. Jahnig, J. Trowsdale, and S. M. van Ham. 1997. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc. Natl. Acad. Sci. USA 94: 13163-13168.
27. Nicholson, M. J., B. Moradi, N. P. Seth, X. Xing, G. D. Cuny, R. L. Stein, and K. W. Wucherpfennig. 2006. Small molecules that enhance the catalytic efficiency of HLA-DM. J. Immunol. 176: 4208-4220.
28. Day, C. L., N. P. Seth, M. Lucas, H. Appel, L. Gauthier, G. M. Lauer, G. K. Robbins, Z. M. Szczepiorkowski, D. R. Casson, R. T. Chung, et al. 2003. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. 112: 831-842.
29. Krogsgaard, M., K. W. Wucherpfennig, B. Cannella, B. E. Hansen, A. Svejgaard, J. Pyrdol, H. Ditzel, C. Raine, J. Engberg, and L. Fugger. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191: 1395-1412. (Pubitemid 30227126)
30. Ellmerich, S., M. Mycko, K. Takacs, H. Waldner, F. N. Wahid, R. J. Boyton, R. H. King, P. A. Smith, S. Amor, A. H. Herlihy, et al. 2005. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J. Immunol. 174: 1938-1946. (Pubitemid 40223934)
31. Itano, A. A., S. J. McSorley, R. L. Reinhardt, B. D. Ehst, E. Ingulli, A. Y. Rudensky, and M. K. Jenkins. 2003. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19: 47-57.
32. Pape, K. A., D. M. Catron, A. A. Itano, and M. K. Jenkins. 2007. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26: 491-502.
33. Van den Broeck, W., A. Derore, and P. Simoens. 2006. Anatomy and nomen-clature of murine lymph nodes: descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J. Immunol. Methods 312: 12-19. (Pubitemid 43795993)
34. Ito, K., H. J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D. R. Bolin, R. Arceo, R. Campbell, et al. 1996. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183: 2635-2644. (Pubitemid 26192372)
35. Wucherpfennig, K. W., A. Sette, S. Southwood, C. Oseroff, M. Matsui, J. L. Strominger, and D. A. Hafler. 1994. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179: 279-290.
36. Marin-Esteban, V., K. Falk, and O. Rotzschke. 2004. "Chemical analogues" of HLA-DM can induce a peptide-receptive state in HLA-DR molecules. J. Biol. Chem. 279: 50684-50690. (Pubitemid 40017805)
37. Chicz, R. M., R. G. Urban, J. C. Gorga, D. A. Vignali, W. S. Lane, and J. L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178: 27-47. (Pubitemid 23173241)
38. Smith, K. J., J. Pyrdol, L. Gauthier, D. C. Wiley, and K. W. Wucherpfennig. 1998. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188: 1511-1520. (Pubitemid 28489588)
39. Vogt, A. B., H. Kropshofer, G. Moldenhauer, and G. J. Hammerling. 1996. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLADM. Proc. Natl. Acad. Sci. USA 93: 9724-9729.
40. van Ewijk, W., P. J. Brekelmans, R. Jacobs, and E. Wisse. 1988. Lymphoid microenvironments in the thymus and lymph node. Scanning Micros. 2: 2129-2140.
41. Lanzavecchia, A. 1985. Antigen-specific interaction between T and B cells. Nature 314: 537-539.
42. Lanzavecchia, A. 1986. Antigen presentation by B lymphocytes: a critical step in T-B collaboration. Curr. Top. Microbiol. Immunol. 130: 65-78.
43. Delamarre, L., R. Couture, I. Mellman, and E. S. Trombetta. 2006. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203: 2049-2055. (Pubitemid 44352226)
44. Hopner, S., K. Dickhaut, M. Hofstatter, H. Kramer, D. Ruckerl, J. A. Soderhall, S. Gupta, V. Marin-Esteban, R. Kuhne, C. Freund, et al. 2006. Small organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket. J. Biol. Chem. 281: 38535-38542. (Pubitemid 46041978)
45. Gupta, S., S. Hopner, B. Rupp, S. Gunther, K. Dickhaut, N. Agarwal, M. C. Cardoso, R. Kuhne, K. H. Wiesmuller, G. Jung, et al. 2008. Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules. PLoS ONE 3: e1814. (Pubitemid 351917376)
46. Belmares, M. P., R. Busch, K. W. Wucherpfennig, H. M. McConnell, and E. D. Mellins. 2002. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J. Immunol. 169: 5109-5117.
47. Illes, Z., J. N. Stern, J. Reddy, H. Waldner, M. P. Mycko, C. F. Brosnan, S. Ellmerich, D. M. Altmann, L. Santambrogio, J. L. Strominger, and V. K. Kuchroo. 2004. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc. Natl. Acad. Sci. USA 101: 11749-11754. (Pubitemid 39095367)
48. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.